Processa Pharmaceuticals, Inc. Segments Disclosure
Note 11 – Segment Reporting
We manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our CODM, our Chief Executive Officer manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss as consolidated net loss.
The accounting policies of our single operating segment are the same as those described in the summary of significant accounting policies in Note 2. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. In 2025 and 2024, all our long-lived assets were held in the United States. Expenditures for the addition of long-lived assets are reported on the consolidated statements of cash flows as purchases of property and equipment. We do not have intra-entity sales or transfers since our only subsidiary is currently dormant.
The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the years ended December 31, 2025 and 2024:
| Year ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Preclinical, clinical trial and other costs | $ | 6,240,583 | $ | 5,450,963 | ||||
| Research and development personnel expense(1) | 1,569,754 | 1,818,183 | ||||||
| General and administrative personnel expense(2) | 2,786,832 | 1,981,756 | ||||||
| Administrative and facilities expense(3) | 3,391,336 | 2,800,304 | ||||||
| Other income, net | (424,671 | ) | (201,088 | ) | ||||
| Total | $ | 13,563,834 | $ | 11,850,118 | ||||
| (1) | Research and development personnel costs include employee stock-based compensation expense of $ and $ for the year ended December 31, 2025 and 2024, respectively. |
| (2) | General and administrative personnel costs include employee stock-based compensation expense of $ and $ for the year ended December 31, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC. |
| (3) | Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs. |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 18, 2026 | Showing above |
| 2024 | Mar 20, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.